Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. WuXi Biologics (Cayman) Inc.
  6. News
  7. Summary
    2269   KYG970081173

WUXI BIOLOGICS (CAYMAN) INC.

(2269)
  Report
Delayed Hong Kong Stock Exchange  -  03:08:49 2023-02-03 am EST
65.95 HKD   -3.16%
02/02Wuxi Biologics Cayman : XDC and Cidara Therapeutics Expand Collaboration to Advance Cidara's Oncology DFC Program
PU
01/19First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China
AQ
01/17Trending: Wuxi Biologics Shareholder Plans Block Sale
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wuxi Biologics Inc. Announces Appointments to Strategy Committee

11/23/2022 | 07:28am EST

The board of directors of WuXi Biologics (Cayman) Inc. announced that Mr. William Robert Keller and Mr. Kenneth Walton Hitchner III have been appointed as members of the strategy committee of the Company by the Board with effect from November 23, 2022. Since joining the Group, Mr. Keller and Mr. Hitchner have been providing advice to the Board as independent non-executive directors of the Company. Their wealth of experience in the pharmaceutical industry has been valuable in expanding the Group's capabilities and capacity to provide a comprehensive and integrated CRDMO platform of services for global customers.

Biographical details of Mr. Keller and Mr. Hitchner are set out in the Company's annual report for the year ended December 31, 2021. As at the date of this announcement, the Strategy Committee comprises Dr. Zhisheng Chen (chairman), Dr. Ge Li, Mr. Yibing Wu, Dr. Weichang Zhou, Mr. Keller and Mr. Hitchner.


ę S&P Capital IQ 2022
All news about WUXI BIOLOGICS (CAYMAN) INC.
02/02Wuxi Biologics Cayman : XDC and Cidara Therapeutics Expand Collaboration to Advance Cidara..
PU
01/19First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment..
AQ
01/17Trending: Wuxi Biologics Shareholder Plans Block Sale
DJ
01/17WuXi Biologics (Cayman) Substantial Shareholder to Place 56 Million Shares; Shares Slip..
MT
01/17Wuxi Biologics' Major Shareholder Plans to Sell 1.3% Stake
CI
01/17Wuxi Biologics Drops After Major Shareholder Plans to Sell 1.3% Stake
DJ
01/12Wuxi Biologics Cayman : 41th Annual J.P. Morgan Healthcare Conference Presentation (in
PU
01/05WuXi Biologics signs exclusive deal with GSK
AN
01/05Trending: Wuxi Biologics Licenses Tumor Antibodies to GSK
DJ
01/04Wuxi Biologics And Gsk Enter Into License Agreement On Multiple Novel Bi- & Multi-Speci..
RE
More news
Analyst Recommendations on WUXI BIOLOGICS (CAYMAN) INC.
More recommendations
Financials
Sales 2022 15 253 M 2 267 M 2 267 M
Net income 2022 4 790 M 712 M 712 M
Net cash 2022 5 060 M 752 M 752 M
P/E ratio 2022 52,3x
Yield 2022 -
Capitalization 247 B 36 688 M 36 688 M
EV / Sales 2022 15,9x
EV / Sales 2023 11,5x
Nbr of Employees 10 593
Free-Float 84,3%
Chart WUXI BIOLOGICS (CAYMAN) INC.
Duration : Period :
WuXi Biologics (Cayman) Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends WUXI BIOLOGICS (CAYMAN) INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 29
Last Close Price 58,42 CNY
Average target price 90,16 CNY
Spread / Average Target 54,3%
EPS Revisions
Managers and Directors
Zhi Sheng Chen Director
Ming Tu Chief Financial Officer & Executive Vice President
Ge Li Non-Executive Chairman
Weichang Zhou Chief Technology Officer & Executive Director
William Robert Keller Independent Non-Executive Director
Sector and Competitors